eg-covid-001
VaccineexperimentalCOVID-19
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 22, 2022 (NCT05188469)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- SARS-CoV-2Immunity, active
SARS-CoV-2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06099613 | Phase 1/Phase 2 (Phase 2) | Oct 23, 2023 | EyeGene Inc., Nucleus Network Ltd |
| NCT05188469 | Phase 1/Phase 2 (Phase 2) | Mar 22, 2022 | EyeGene Inc., Novotech |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EyeGene Inc. | For profit | 2 | 2 | 1 | 2022 |
| Novotech | For profit | 1 | 0 | 1 | 2022 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1